IL-6 causes multiple effects in androgen-sensitive and -insensitive prostate cancer cell lines

References

• Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res.1, 293–297 (1941).
   Google Scholar
• Twillie DA, Esenberger MA, Carducci MA et al. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology45, 542–549 (1995).
   PubMedGoogle Scholar
• Adler HL, McCurdy MA, Kattan MW et al. Elevated levels of circulating interleukin-6 and transforming growth factor-β1 in patients with metastatic prostatic carcinoma. J. Urol.161, 182–187 (1999).
   PubMed Web of Science ®Google Scholar
• Nakashima J, Tachibana M, Horiguchi Y et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin. Cancer Res.6, 2702–2706 (2000).
   PubMed Web of Science ®Google Scholar
• Hobisch A, Rogatsch H, Hittmair A et al. Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J. Pathol.191, 239–244 (2000).
   PubMed Web of Science ®Google Scholar
• Hobisch A, Culig Z, Radmayr C et al. Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res.55, 3068–3072 (1995).
   PubMed Web of Science ®Google Scholar
• Jarrard DF, Kinoshita H, Shi Y et al. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Res.58, 5310–5314 (1998).
   PubMed Web of Science ®Google Scholar
• Visakorpi T, Hyytinen E, Koivisto P et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet.9, 401–406 (1995).
   PubMed Web of Science ®Google Scholar
• Kokontis J, Takakura K, Hay N et al. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res.54, 1566–1573 (1994).
   PubMed Web of Science ®Google Scholar
• Culig Z, Hoffmann J, Erdel M et al. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br. J. Cancer81, 242–251 (1999).
   PubMed Web of Science ®Google Scholar
• Montgomery RB, Mosthagel EA, Vessella R et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res.68, 4447–4454 (2008).
   PubMed Web of Science ®Google Scholar
• Culig Z, Klocker H, Bartsch G et al. Androgen receptors in prostate cancer. J. Urol.170, 1363–1369 (2003).
   PubMedGoogle Scholar
• Culig Z, Hobisch A, Cronauer MV et al. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol. Endocrinol.7, 1541–1550 (1993).
   PubMed Web of Science ®Google Scholar
• Comuzzi B, Lambrinidis L, Rogatsch H et al. The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function. Am. J. Pathol.162, 233–241 (2003).
   PubMed Web of Science ®Google Scholar
• Comuzzi B, Nemes C, Schmidt S et al. The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer. J. Pathol.204, 159–166 (2004).
   PubMed Web of Science ®Google Scholar
• Heemers HV, Sebo TJ, Debes JD et al. Androgen deprivation increases p300 expression in prostate cancer cells. Cancer Res.67, 3422–3430 (2007).
   PubMed Web of Science ®Google Scholar
• Yan J, Yu CT, Ozen M et al. Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor/AKT signaling pathway. Cancer Res.66, 11039–11046 (2006).
   PubMedGoogle Scholar
• Ignar-Trowbridge DM, Teng CT, Ross KA et al. Peptide growth factors elicit estrogen receptor-dependent transcriptional activation of an estrogen-responsive element. Mol. Endocrinol.7, 992–998 (1993).
   PubMed Web of Science ®Google Scholar
• Culig Z, Hobisch A, Cronauer MV et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res.54, 5454–5478 (1994).
   Google Scholar
• Nazareth LV, Weigel NL. Activation of the human androgen receptor through a protein kinase A signaling pathway. J. Biol. Chem.271, 19900–19907 (1996).
   PubMed Web of Science ®Google Scholar
• Sadar MD, Gleave ME. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells. Cancer Res.60, 5825–5831 (2000).
   PubMed Web of Science ®Google Scholar
• Craft N, Shostak Y, Carey M et al. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat. Med.5, 280–285 (1999).
   PubMed Web of Science ®Google Scholar
• Mori S, Murakami-Mori K, Bonavida B. Interleukin-6 induces G1 arrest through induction of p27 (Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells. Biochem. Biophys. Res. Commun.257, 609–614 (1999).
   PubMed Web of Science ®Google Scholar
• Giri D, Ozen M, Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am. J. Pathol.159, 2159–2165 (2001).
   PubMed Web of Science ®Google Scholar
• Hobisch A, Ramoner R, Fuchs D et al. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Clin. Cancer Res.7, 2941–2948 (2001).
   PubMed Web of Science ®Google Scholar
• Hobisch A, Eder IE, Putz T et al. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res.58, 4640–4645 (1998).
   PubMed Web of Science ®Google Scholar
• Chung TD, Yu JJ, Kong TA et al. Interleukin-6 activates phosphatidylinositol 3-kinase, which inhibits apoptosis in human prostate cancer cell lines. Prostate42, 1–7 (2000).
   PubMed Web of Science ®Google Scholar
• Malinowska K, Neuwirt H, Cavarretta IT et al. Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr. Rel. Cancer16, 155–169 (2009).
   PubMed Web of Science ®Google Scholar
• Wang Q, Horiatis D, Pinski J. Interleukin-6 inhibits the growth of prostate cancer xenografts in mice by the process of neuroendocrine differentiation. Int. J. Cancer111, 508–513 (2004).
   PubMedGoogle Scholar
• Debes JD, Schmidt LJ, Huang H et al. p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res.62, 5632–5636 (2002).
   PubMed Web of Science ®Google Scholar
• Ueda T, Mawji NR, Bruchovsky N et al. Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J. Biol. Chem.277, 38087–38094 (2002).
   PubMedGoogle Scholar
• Debes J, Sebo TJ, Lohse CM et al. p300 in prostate cancer proliferation and progression. Cancer Res.63, 7638–7640 (2003).
   PubMed Web of Science ®Google Scholar
• Steiner H, Berger AP, Godoy-Tundidor S et al. An autocrine loop for vascular endothelial growth factor is established in prostate cancer cells generated after prolonged treatment with interleukin 6. Eur. J. Cancer40, 1066–1072 (2004).
   PubMed Web of Science ®Google Scholar
• Seaton A, Scullin P, Maxwell PJ et al. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. Carcinogenesis29, 1148–1156 (2008).
   PubMedGoogle Scholar
• Lee SQ, Lou W, Hou M et al. Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway. Oncogene22, 7981–7988 (2003).
   PubMedGoogle Scholar
• Smith PC, Keller ET. Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. Prostate48, 47–53 (2001).
   PubMed Web of Science ®Google Scholar
• Wallner L, Dai J, Escara-Wilke J et al. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. Cancer Res.66, 3087–3095 (2006).
   PubMedGoogle Scholar
• Steiner H, Cavarretta IT, Moser P et al. Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328. Prostate66, 1744–1752 (2006).
   PubMedGoogle Scholar
• Zaki MH, Nemeth JA, Trikha M. CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. Int. J. Cancer111, 592–595 (2004).
   PubMed Web of Science ®Google Scholar
• Dorff TB, Goldman B, Pinski JK et al. Clinical and correlative results of SWOG S0354: a Phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin. Cancer Res.16, 3028–3034 (2010).
   PubMed Web of Science ®Google Scholar
• Karkera J, Steiner H, Li W et al. The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a Phase I study. Prostate DOI: 10.1002/pros.21362 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Bellezza I, Neuwirt H, Nemes C et al. Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer. Am. J. Pathol.169, 2199–2208 (2006).
   PubMedGoogle Scholar
• Puhr M, Santer FR, Neuwirt H et al. Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways. Cancer Res.69, 7375–7384 (2009).
   PubMedGoogle Scholar
• Pierconti F, Martin M, Pinto F et al. Epigenetic silencing of SOCS3 identifies a subset of prostate cancer with an aggressive behavior. Prostate71, 318–325 (2011).
   PubMed Web of Science ®Google Scholar
• Puhr M, Santer FR, Neuwirt H et al. SOCS-3 antagonises the proliferative and migratory effects of fibroblast growth factor-2 in prostate cancer by inhibition of p44/p42 MAPK signalling. Endocr. Relat. Cancer17, 525–538 (2010).
   PubMedGoogle Scholar
• Neuwirt H, Puhr M, Cavarretta IT et al. Suppressor of cytokine signalling-3 is up-regulated by androgen in prostate cancer cell lines and inhibits androgen-mediated proliferation and secretion. Endocr. Relat. Cancer14, 1007–1019 (2007).
   PubMedGoogle Scholar